Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hang On To Those Ex-U.S. Rights, Biotech Veterans Termeer And Mullen Advise Start-Ups

This article was originally published in The Pink Sheet Daily

Executive Summary

The two 30-year industry veterans talked about lessons learned, regulatory climate change and health care reform at MassBio's annual meeting in Boston.

You may also be interested in...

Genzyme's Manufacturing Problems Lead To Enforcement Action By FDA

FDA tells Genzyme a consent decree to ensure GMP compliance is likely, but firm notes sanctions would be related only to Allston Landing facility.

Agreement Averts Another Proxy Fight Between Biogen Idec, Icahn

Despite agreeing to support Biogen's nominee slate, Icahn says he still will push for biotech sale.

Varied Outcomes Predicted On Icahn's Bid For Four Seats On Genzyme's Board

Activist investor Carl Icahn seeking the kind of gains similar to those he realized at Biogen Idec.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts